antihemophilic factor

(redirected from Advate)
Also found in: Dictionary, Thesaurus, Medical.

antihemophilic factor

[¦an·tē‚hē·mə′fil·ik ‚fak·tər]
(biochemistry)
A soluble protein clotting factor in mammalian blood. Also known as factor VIII; thromboplastinogen.
References in periodicals archive ?
These collaborations focus on further advancing ADVATE, with the objective of reducing the frequency of infusions and enhancing quality of life for hemophilia patients.
This launch follows the US Food and Drug Administration's (FDA) approval of ADYNOVATE [Antihemophilic Factor (Recombinant), PEGylated], an extended circulating half-life recombinant factor VIII (rFVIII) treatment for hemophilia A based on full-length ADVATE [Antihemophilic Factor (Recombinant)].
7 billion, up 8%, driven primarily by double-digit growth and continued strong demand for hemophilia therapies (+11% to $942 million), including ADVATE [Antihemophilic Factor (Recombinant), Plasma/Albumin-Free Method] and FEIBA (an inhibitor therapy).
Baxter International achieved positive results from its Phase III trial of BAX 855, an investigational, extended half-life recombinant factor VIII (rFVIII) treatment for hemophilia A based on ADVATE, which met its primary endpoint in reducing annualized bleed rates (ABR) in the prophylaxis arm compared to the on-demand arm.
M2 EQUITYBITES-April 25, 2014-Baxter wins US FDA's approval for ADVATE with BAXJECT III reconstitution system for treating patients with hemophilia A
M2 PHARMA-April 25, 2014-Baxter wins US FDA's approval for ADVATE with BAXJECT III reconstitution system for treating patients with hemophilia A
163/2006, for the award of the supply of the drug Advate for a period of 4 months.
The current suite supports the processing of ADVATE [Antihemophilic Factor (Recombinant)], the company's recombinant factor VIII (rFVIII) for the treatment of patients with hemophilia A.